Biomolecules · Nov 20, 2026
Beyond Glucose Control: The Emerging Role of GLP-1 Receptor Agonists in Rheumatic and Musculoskeletal Diseases
By Yokoyama YM, Watanabe R, Shiomi M et al.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become established therapies for type 2 diabetes mellitus and obesity, with robust evidence demonstrating cardiovascular and renal benefits beyond glycemic control. Increasing evidence indicates that glucagon-like peptide-1 (GLP-1), an incretin hormone, exerts pleiotropic effects extending beyond metabolic regulation, including modulation of appetite, oxidative stress, endothelial function, and systemic inflammation. These properties have generated considerable interest in the potential role of GLP-1RAs in immune-mediated diseases. Rheumatic and musculoskeletal diseases (RMDs) are frequently accompanied by obesity and metabolic comorbidities, both of which contribute to chronic inflammation, increased cardiovascular risk, and poorer clinical outcomes. In addition to improving metabolic health, experimental studies suggest that GLP-1RAs may modulate innate and adaptive immune responses through mechanisms involving macrophage polarization, NF-κB signaling, T-cell responses, and pro-inflammatory cytokine production. These immunometabolic effects suggest that GLP-1RAs may have therapeutic potential as adjunctive agents capable of attenuating disease activity and improving clinical outcomes in selected patients with RMDs. Conversely, emerging genetic and observational studies have reported conflicting associations between GLP-1R signaling or GLP-1RA exposure and autoimmune disease risk, while disease-specific safety data remain limited. This review summarizes the metabolic and immunological mechanisms of selective GLP-1RAs, critically appraises the available evidence for their use in RMDs, and separately discusses emerging evidence involving dual GIP/GLP-1 and triple GIP/GLP-1/glucagon receptor agonists, highlighting their distinct pharmacological profiles, current limitations, and future research directions in rheumatology.